Kidney Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter, and initial lack of function of the new kidney. Its treatment includes immunosuppressive drugs that aid in preventing organ rejection.

The Kidney Transplant Rejection pipeline market research report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects.

Key Targets in the Kidney Transplant Rejection Pipeline Products Market

The key targets in the Kidney Transplant Rejection pipeline products market are CD40 Ligand, T Cell Specific Surface Glycoprotein CD28, T Lymphocyte Activation Antigen CD80, Tyrosine Protein Kinase SYK, 20s Proteasome, Calcineurin, Cells Expressing B Lymphocyte Antigen CD20, Complement C1s Subcomponent, Complement C3, General Transcription And DNA Repair Factor IIH Helicase Subunit XPB, and others.

Kidney Transplant Rejection Pipeline Products Market, by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Kidney Transplant Rejection Pipeline Products Market

The key mechanisms of action in the Kidney Transplant Rejection pipeline products market are CD40 Ligand Inhibitor, T Cell Specific Surface Glycoprotein CD28 Antagonist, T Lymphocyte Activation Antigen CD80 Inhibitor, Tyrosine Protein Kinase SYK Inhibitor, 20s Proteasome Inhibitor, Calcineurin Inhibitor, Complement C1s Subcomponent Inhibitor, Complement C3 Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, General Transcription And DNA Repair Factor IIH Helicase Subunit XPB Inhibitor, and others.

Kidney Transplant Rejection Pipeline Products Market, by MoA

For more MoA insights, download a free report sample

Key Routes of Administration in the Kidney Transplant Rejection Pipeline Products Market

The key routes of administration in the Kidney Transplant Rejection pipeline products market are intravenous, subcutaneous, oral, parenteral, intramuscular, and intravenous drip.

Kidney Transplant Rejection Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Kidney Transplant Rejection Pipeline Products Market

The key molecule types in the Kidney Transplant Rejection pipeline products market are monoclonal antibody, cell therapy, small molecule, fusion protein, gene-modified cell therapy, antibody, peptide, recombinant enzyme, recombinant protein, recombinant vector vaccine, and subunit vaccine.

Kidney Transplant Rejection Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Major Companies in the Kidney Transplant Rejection Pipeline Products Market

Some of the major companies in the Kidney Transplant Rejection pipeline products market are Astellas Pharma Inc, Medeor Therapeutics Inc, Bristol-Myers Squibb Co, Eledon Pharmaceuticals Inc, Hillhurst Biopharmaceuticals Inc, Junten Bio Co Ltd, OSE Immunotherapeutics, Sangamo Therapeutics Inc, Talaris Therapeutics Inc, and Alphamab Oncology.

Kidney Transplant Rejection Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Kidney Transplant Rejection Pipeline Products Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).
• The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.